Zevra Therapeutics Yönetim
Yönetim kriter kontrolleri 0/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
Neil McFarlane
İcra Kurulu Başkanı
US$3.4m
Toplam tazminat
| CEO maaş yüzdesi | 4.6% |
| CEO görev süresi | 1.1yrs |
| CEO sahipliği | n/a |
| Yönetim ortalama görev süresi | 1.8yrs |
| Yönetim Kurulu ortalama görev süresi | 1.6yrs |
Son yönetim güncellemeleri
Recent updates
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%
Aug 30
Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors
Jul 12Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically
Apr 07Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
Apr 04Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
Apr 02Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
Dec 28Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts
Sep 05This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year
Aug 20Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable
Apr 17US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results
Mar 10Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?
Mar 08Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates
Nov 16Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?
Nov 11KemPharm posts Phase 1 data to support further studies for sleep disorder therapy
Sep 28KemPharm wins Buy rating at Canaccord on CNS focus
Sep 15KemPharm - Redesigning Approved Drugs For Better Efficacy And Safety
Jun 28KemPharm exercises existing warrants and issues new ones in private placement
Jun 18KemPharm reports orange book listing for six U.S. patents covering serdexmethylphenidate
May 26CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$67m |
| Mar 31 2024 | n/a | n/a | -US$49m |
| Dec 31 2023 | US$3m | US$158k | -US$46m |
Tazminat ve Piyasa: Neil 'nin toplam tazminatı ($USD 3.45M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.40M ).
Tazminat ve Kazançlar: Neil şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.
CEO
Neil McFarlane (51 yo)
1.1yrs
Görev süresi
US$3,445,231
Tazminat
Mr. Neil F. McFarlane serves as President & Chief Executive Officer at Zevra Therapeutics, Inc. since October 10, 2023 and serves as its Director since October 9, 2023. He has served as Director at Collegi...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 1.1yrs | US$3.45m | Veri yok | |
| Co-Founder & Chief Development Officer | no data | US$1.67m | 0.052% $ 228.6k | |
| CFO, Secretary & Treasurer | 9.4yrs | US$2.26m | 0.035% $ 155.1k | |
| Chief Commercial Officer & Executive VP of Business Development | 1.8yrs | US$1.82m | 0.0066% $ 29.4k | |
| Chief Scientific Officer | 1.8yrs | US$1.08m | 0.0052% $ 23.0k | |
| Vice President of Investor Relations & Corporate Communications | 2.3yrs | Veri yok | Veri yok | |
| Chief Legal Officer | less than a year | Veri yok | Veri yok | |
| Chief People Officer | less than a year | Veri yok | Veri yok | |
| Senior Vice President of Manufacturing | 1.8yrs | Veri yok | Veri yok | |
| Senior Vice President of Clinical Development | 1.8yrs | Veri yok | Veri yok | |
| Senior Vice President of Medical Affairs & Advocacy | 1.8yrs | Veri yok | Veri yok | |
| Chief Medical Officer | less than a year | Veri yok | Veri yok |
1.8yrs
Ortalama Görev Süresi
52yo
Ortalama Yaş
Deneyimli Yönetim: ZVRA 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 1.1yrs | US$3.45m | Veri yok | |
| Independent Director | 1.6yrs | US$274.00k | 0% $ 0 | |
| Independent Director | 1.6yrs | US$258.02k | 0% $ 0 | |
| Independent Chair | 3.3yrs | US$324.39k | 0.0014% $ 6.1k | |
| Member of Scientific and Medical Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 1.6yrs | US$264.31k | 0.057% $ 252.0k | |
| Independent Director | 1.6yrs | US$260.67k | 0.0029% $ 12.6k | |
| Chairman of Scientific and Medical Advisory Board | 17.8yrs | Veri yok | Veri yok | |
| Member of Scientific & Medical Advisory Board | no data | Veri yok | Veri yok | |
| Co-Chair of Physician Advisory Council | 11.1yrs | Veri yok | Veri yok | |
| Co-Chair of Physician Advisory Council | 11.1yrs | Veri yok | Veri yok | |
| Independent Director | 1.3yrs | US$243.04k | 0.038% $ 168.0k |
1.6yrs
Ortalama Görev Süresi
58yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ZVRA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.6 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.